Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

183.81 -3.12 (-1.67%)
Streaming Delayed Price Updated: 10:34 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Present at Stifel 2024 Healthcare Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment... 
From Palvella Therapeutics
Via GlobeNewswire
News headline image
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports Second Quarter 2024 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
5 Best Short-Term Stocks to Consider Investing In
Looking for the best short-term stocks? Explore our top picks and learn how to navigate the risks and opportunities in fast-paced stock trading. 
Via MarketBeat
News headline image
Ligand to Acquire APEIRON Biologics AG for $100 Million
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
News headline image
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Participate in Upcoming Investor Conferences
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports First Quarter 2024 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
News headline image
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
From Ligand Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.